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Previous cerebrovascular disease is an important predictor of 
clinical outcomes in elderly patients with percutaneous coronary 
interventions: The Nobori-Biolimus eluting stent prospective 
multicenter 1-year observational registry in South Korea
Introduction
The number of elderly people is increasing rapidly, as life 
expectancy increases and overall health improves. Age is one 
of the major important cardiovascular risk factor, and coro-
nary artery disease (CAD) is the most common cause of death 
in the elderly (1). Elderly patients have a high prevalence of 
calcified lesions, tortuous lesions, multi-vessel disease, and 
left main coronary artery stenosis (2). In the past, elderly pa-
tients who had undergone elective percutaneous coronary in-
tervention (PCI) showed lower procedural success rates and 
higher complication rates (3–5). Notwithstanding the high-risk 
aspects of PCI, advances in PCI device technology and im-
provements in medical therapy have reduced the adverse car-
diovascular event rates after PCI in elderly patients (6, 7). PCI 
is being increasingly performed on elderly patients because 
of acceptable periprocedural outcomes and long-term survival 
rates (8).
However, the efficacy of PCI in elderly patients has not been 
well studied because elderly patients are less commonly en-
rolled in randomized, controlled clinical trials, and observational 
studies include only relatively small numbers of elderly patients. 
The appropriate selection of elderly patients for revasculariza-
tion is become increasingly important because these subsets of 
patients are more likely to experience a major cardiac or cereb- 
rovascular event after PCI.
Objective: The appropriate selection of elderly patients for revascularization has become increasingly important because these subsets of 
patients are more likely to experience a major cardiac or cerebrovascular event—percutaneous coronary intervention (PCI). The objective of 
this study was to determine important independent risk factor for predicting clinical outcomes in the elderly patients after successful PCI, par-
ticularly in a series of South Korean population.
Methods: This study is prospective, multicenter, observational cross-sectional study. A total of 1,884 consecutive patients who underwent suc-
cessful PCI with Nobori® Biolimus A9-eluting stents were enrolled between April 2010 and December 2012. They were divided into two groups 
according to the age: patients <75 years old (younger patient group) and ≥75 years old (elderly patient group). The primary endpoint was major 
adverse cardiac or cerebrovascular events (MACCE) at 1-year after index PCI.
Results: The 1-year cumulative incidence of MACCE (12.9% vs. 4.3%, p<0.001) and total death (7.1% vs. 1.5%, p<0.001) was significantly higher in 
the elderly group than in younger group. Previous cerebrovascular disease was significantly correlated with MACCE in elderly patients 1-year 
after PCI (hazard ratio, 2.804; 95% confidence interval, 1.290–6.093 p=0.009).
Conclusion: Previous cerebrovascular disease is important independent predictor of the MACCE in elderly patients at 1-year after PCI with 
Nobori® Biolimus A9-eluting stents especially in a series of South Korean population. Therefore, careful PCI with intensive monitoring and man-
agement can improve major clinical outcomes after successful PCI in elderly patients with previous cerebrovascular disease compared with 
younger patients. (Anatol J Cardiol 2017; 18: 128-35)
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We aimed to investigate an important determinant risk fac-
tor that might predict clinical outcomes following successful PCI 
with Nobori® Biolimus A9-eluting stents in elderly patients dur-
ing the 1-year follow-up period, particularly in a series of South 
Korean population.
Methods
This study was a prospective, multicenter, observational 
single-arm study that gathered data from 20 centers in South Ko-
rea that performed PCI using Nobori stents (Nobori® Biolimus-
eluting stent, Terumo, Tokyo, Japan). The Nobori® stent is a new-
generation drug-eluting stent (DES) that comprises a stainless 
steel alloy stent with a strut thickness of 120 µm that is coated 
on the abluminal surface with a matrix containing the highly li-
pophilic sirolimus analog, Biolimus A9, and a biodegradable poly-
lactic acid polymer (9). 
The definition of an elderly person varies among different 
studies, and while there is no consensus about who should be 
considered elderly, the 2002 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines for the mana- 
gement of acute coronary syndromes consider patients aged 
>75 years to be an “at-risk” group (10).
Detailed patient data were collected from each hospital 
by a study coordinator or physician who entered the data into 
a web-based, computerized database. Information about a pa-
tient’s clinical status at the most recent follow-up assessment 
was gathered through clinic visits and/or telephone interviews. 
One year after the index procedure, all patients who had under-
gone PCI were advised to undergo angiographic follow-up as-
sessments. 
All patients provided written informed consent to participate 
in this study. The study protocol was reviewed and approved by 
the institutional review boards of the participating centers.
Study population
From April 2010 to December 2012, a total of 2,012 consecu-
tive patients who underwent successful PCI were enrolled in 
this study. Among them, 128 patients were excluded because of 
death, follow-up loss, and not participating (Fig. 1). The remai- 
ning 1,884 patients (93.6%) completed 1-year follow-up. We clas-
sified them into either younger group (aged <75 years, n=1,519) 
or the elderly group (aged ≥75 years, n=365). This was an “all-
comers” trial of routine clinical practice undertaken in a real-
world setting. 
PCI procedure and medical treatment
A diagnostic coronary angiography (CAG) and PCI were done 
through either the femoral or radial artery after an administra-
tion of unfractionated heparin (70–100 IU/kg). Patient’s activated 
clotting time was maintained above 250 s during the procedure. 
Revascularization was considered clinically indicated when the 
patient had angina and/or signs of ischemia and ≥50% diameter 
restenosis by angiography or ≥70% diameter restenosis even in 
the absence of signs and symptoms. The use of cilostazol - Ple-
taal® (Otsuka Pharmaceutical Co., Tokyo, Japan) or platelet gly-
coprotein IIb/IIIa receptor blockers was left to the discretion of 
the individual operators. A successful PCI was defined as the 
achievement of an angiographic residual stenosis less than 30% 
and final thrombolysis in myocardial infarction (MI) blood flow 
grade equal to 3. During hospitalization, enrolled patients had tak-
en cardiovascular beneficial medications, including beta-blockers 
(BB), angiotensin-converting enzyme inhibitors (ACEI), angioten-
sin receptor blockers (ARB), calcium channel blockers (CCB), and 
lipid-lowering agents. After discharge, the patients were encour-
aged to stay on the same medications they received during hos-
pitalization. Dual anti-platelet therapy, which was the combination 
of aspirin (100 mg/day) and clopidogrel (75 mg/day), was adminis-
tered for at least 12 months to patients who had undergone PCI.
Study definitions and clinical follow-up
Patients with systolic blood pressure of at least 140 mm Hg 
or diastolic blood pressure of at least 90 mm Hg or who were 
taking antihypertensive medications were defined as ha- 
ving hypertension. Patients with serum low-density lipoprotein 
cholesterol concentrations of at least 140 mg/dL, high-density 
lipoprotein cholesterol concentrations <40 mg/dL, triglyceride 
concentrations were ≥150 mg/dL, or patients who were taking 
lipid-lowering medication were defined as having dyslipidemia 
(11). Patients whose fasting blood glucose concentrations were 
at least 126 mg/dL and/or whose hemoglobin A1c levels were 
at least 6.5% for at least 1 year before drug or dietary interven-
tions and before they were enrolled in this study or those who 
were taking anti-diabetic medications were defined as diabetic. 
Peripheral vascular disease was diagnosed on the basis of the 
ankle-brachial pressure index (<0.9) or computed tomographic 
angiographic findings. Renal dysfunction was defined as an esti-
mated glomerular filtration rate (GFR) of <60 mL/min/1.73 m2.
The recordings of cardiovascular risk factors and past medi-
cal histories were based on patient self-report. All deaths were 
A total 2.012 consecutive patients with stable angina or acute coronary 
syndrome who underwent successful PCI with unrestricted Nobori® 
biolimus-eluting stent implantion between April 2010 and December 2012 
20 centers in South Korea







– Follow-up loss (n=63)
– Not participate (n=59)
Figure 1. Flowchart of the study patients
PCI - percutaneous coronary intervention
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classified cardiac in origin unless a non-cardiac cause could 
be documented. MI was defined as the presence of clinical 
symptoms, electrocardiographic changes, or abnormal ima- 
ging findings of MI, combined with an increase in the creatine 
kinase myocardial band fraction above the upper normal limits 
or an increase in troponin-T/troponin-I to greater than the 99th 
percentile of the upper normal limit. Target lesion revasculariza-
tion (TLR) was defined as a revascularization of the target lesion 
due to restenosis or reocclusion within the stent or 5 mm in and 
adjacent of the distal or proximal segment. Target vessel revas-
cularization (TVR) was defined as revascularization of the target 
vessel or any segment of the coronary artery containing the tar-
get lesion. The primary endpoint of this study was major adverse 
cardiac or cerebrovascular events (MACCE) at 1 year. Major ad-
verse cardiac events (MACE) were defined as the composite of 
total death, non-fatal MI, TLR, TVR, and non-TVR. All participants 
were required to visit the outpatient department of cardiology at 
the end of the first month and then every 3 to 6 months after the 
index PCI procedure as well as whenever angina-like symptoms 
occurred. The cumulative incidence of various MACCE during 1 
year was compared between the 2 groups. In this study, all pa-
tients completed 1-year clinical follow-up through face-to-face 
interviews at the outpatient clinic, medical chart review, and 
telephone contacts. In some ambiguous cases, we compared 
patient's biological information with data from the Korean Na-
tional Statistical Office.
Statistical analysis
PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chi-
cago, IL, USA) was used for all statistical analyses. Continuous 
variables were presented as means±standard deviations or as 
medians (interquartile ranges) and were compared using Stu-
dent’s t test or Mann–Whitney U test after appropriate testing 
for normal distributions. Categorical variables, presented as 
numbers and percentages, were compared using the chi-square 
test on the basis of an expected frequency of >5, Fisher’s e- 
xact test, or Pearson’s chi-square test, as appropriate. Univariate 
and multivariate logistic regression analyses were performed to 
determine the risk factors associated with the adverse events. 
Two-tailed p values <0.05 were considered statistically signifi-
cant. Cox proportional hazards regression was used to deter-
mine the independent predictors of 1-year mortality and MACCE.
Results
A total of 1,884 consecutive patients who underwent suc-
cessful PCI with Nobori® Biolimus A9-eluting stents were en-
rolled and 1,519 (80.6%) patients were <75 years old and 365 
(19.4%) were ≥75 years old. Patient's baseline clinical charac-
teristics are summarized in Table 1. The mean age of the younger 
patient group was 60.8±9.3 years, and the mean age of the elderly 
group was 79.4±3.8 years. The elderly group had a higher number 
of hypertension, previous cerebrovascular disease, decreased 
left ventricular ejection fraction (LVEF), decreased body mass 
index (BMI), renal dysfunction, and non-ST segment elevation 
MI (NSTEMI) compared with the younger group. In contrast, the 
younger group contained more smokers and more dyslipidemic 
individuals.
The younger patients were more likely to have one-vessel 
disease but multi-vessel diseases were more frequent in the el-
derly patients. There were no significant differences between 
the groups with respect to the distributions of the ACC/AHA le-
sion types, bifurcation lesions, or treated vessels or with respect 
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Table 1. Baseline characteristics
  <75 years ≥75 years P 
  (n=1.519) (n=365)
Age, y 60.8±9.3 79.4±3.8 <0.001
Men, n (%) 1129 (74.3) 198 (54.2) <0.001
Hypertension, n (%) 912 (60.0) 257 (70.4) 0.001
Dyslipidemia, n (%) 1197 (78.8) 253 (64.3) <0.001
DM, n (%) 570 (37.3) 143 (39.2) 0.820
Smoker (C-F), n (%) 718 (47.2) 99 (27.1) <0.001
Previous MI, n (%) 75 (4.9) 17 (4.7) 0.707
Previous CVD, n (%) 136 (9.0) 53 (14.5) 0.005
Previous PCI, n (%) 291 (19.2) 65 (17.8) 0.833
Previous CABG, n (%) 35 (2.3) 11 (3.0) 0.714
PVD, n (%) 70 (4.5) 23 (6.1) 0.421
Family history of CAD, n (%) 68 (4.5) 8 (2.2) 0.134
LVEF (%) 57.98±13.1 54.5±14.1 <0.001
NYHA classification
 Class I 1165 (76.7) 286 (78.4) 0.498
 Class II 235 (15.5) 52 (14.2) 0.559
 Class III 109 (7.2) 22 (6.0) 0.439
 Class IV 10 (0.7) 5 (1.4) 0.154
BMI, kg/m2 25.5±19.4 23.1±3.4 0.024
Estimated GFR 402 (26.5) 285 (78.0) <0.001 
[<60 mL/min/1.73 m2, n (%)]
Stable angina, n (%) 668 (44.0) 156 (42.7) 0.696
ACS, n (%) 851 (56.0) 209 (57.2) 0.650
Unstable angina, n (%) 409 (26.9) 96 (26.3) 0.863
NSTEMI, n (%) 164 (10.8) 61 (16.7) 0.002
STEMI, n (%) 278 (18.3) 52 (14.2) 0.054
Data are presented as the means±standard deviations or as numbers and percent-
ages. ACS - acute coronary syndrome; C-F - current or former; CVD - cerebrovascular 
disease; BMI - body mass index; CABG - coronary artery bypass graft; CAD - coronary 
artery disease; DM - diabetes mellitus; GFR - glomerular filtration rate; LVEF - left 
ventricular ejection fraction; MI - myocardial infarction; NYHA - New York Heart As-
sociation; NSTEMI - non-ST segment elevation myocardial infarction; PCI - percuta-
neous coronary intervention; PVD - peripheral vascular disease; STEMI - ST segment 
elevation myocardial infarction
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to the mean numbers of stents per patient, the mean total stent 
lengths, or the mean stent diameters (Table 2).
Figure 2 shows the Kaplan–Meier MACCE-free survival esti-
mates for the elderly patients and the younger patients. The cu-
mulative 1-year incidence of MACCE was 5.9%; when stratified 
according to age; the 1-year incidence was 4.3% in the younger 
group and 12.9% in the elderly group (p<0.001). The cumulative 
1-year mortality rate was 2.6% (49 patients); when stratified ac-
cording to age, the 1-year mortality rate was 1.5% (23 patients) in 
the younger patient group and 7.1% (26 patients) in the elderly pa-
tient group (p<0.001). The rates of MI was 0.6% (nine patients) in 
the younger patient group and 2.5% (12 patients) in the elderly pa-
tient group (p<0.001). However, the revascularization rates (TLR, 
TVR, non-TVR) and cerebrovascular accident (CVA) rates did not 
differ significantly between the groups (Table 3). Table 4 shows 
Table 2. Lesion characteristics
  <75 years ≥75 years P 
  (n=1.519) (n=365)
Number of diseased vessels   0.062
 1, n (%) 738 (48.6) 153 (42.0) 0.022
 2, n (%) 440 (28.9) 115 (31.5) 0.339
 ≥3, n (%) 341 (22.4) 97 (26.6) 0.094
Multi-vessel disease 781 (51.4) 212 (58.1) 0.022
Number of treated vessels
 1, n (%) 1519 (100.0) 365 (100) 1.000
 2, n (%) 145 (9.5) 31 (8.5) 0.535
 ≥3, n (%) 41(2.7) 8 (2.2) 0.584
Number of lesions   0.647
 1, n (%) 1169 (77.0) 274 (75.1) 0.444
 2, n (%) 291 (19.2) 76 (20.8) 0.471
 3, n (%) 48 (3.2) 15 (4.1) 0.365
 4, n (%) 11 (0.7) 0 (0.0) 1.000
Number of treated lesions
 1, n (%) 1519 (100.0) 365 (100.0) 1.000
 2, n (%) 132(8.7) 23 (6.3) 0.136
 3, n (%) 25 (1.6) 5 (1.4) 0.795
 4, n (%) 3 (0.2) 0 (0.0) 1.000
Target vessel location
 Left main, n (%) 52 (3.4) 9 (2.5) 0.575
 Left anterior descending, n (%) 811 (53.4) 205 (56.2) 0.104
 Left circumflex, n (%) 241 (15.9) 54 (14.8) 0.469
 Right coronary, n (%) 415 (27.3) 97 (26.6) 0.567
ACC/AHA type, B2, C lesion, n (%) 1197 (78.8) 291 (79.7) 0.717
IVUS 310 (20.4) 59 (16.2) 0.186
Bifurcation lesions, n (%) 95 (6.3) 24 (6.6) 0.825
Mean number of stents, n 1.10±0.29 1.08±0.27 0.198
Mean total stent length, mm 21.1±7.7 21.6±5.1 0.261
Mean stent diameter, mm 3.07±0.9 3.0±1.3 0.417
Data are presented as the means±standard deviations or as numbers and percent-
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Figure 2. Kaplan-Meier curved analysis of MACCE free survival
MACCE - major adverse cardiac or cerebrovascular events
<75 years old
≥75 years old
Table 3. One year cumulative incidence of adverse cardiac or 
cerebrovascular events
  <75 years ≥75 years Total P 
  (n=1.519) (n=365) (n=1.884)
Death 
 Total, n (%) 23 (1.5) 26 (7.1) 49 (2.6) <0.001
 Cardiac, n (%) 7 (0.5) 17 (4.7) 24 (1.3) <0.001
 Non-cardiac, n (%) 16 (1.1) 9 (2.5) 25 (1.3) 0.034
MI, n (%) 9 (0.6) 12 (2.5) 21 (1.1) <0.001
Revascularization, n (%) 26 (1.7) 6 (1.6) 32 (1.7) 0.928
 TLR, n (%) 10 (0.7) 3 (0.8) 13 (0.7) 0.732
 TVR, n (%) 23 (1.5) 5 (1.4) 28 (1.5) 0.838
 Non-TVR, n (%) 8 (0.5) 2 (0.5) 10 (0.5) 1.000
CVA, n (%) 8 (0.5) 3 (0.8) 11 (0.6) 0.506
Recurrent CVA, n (%)† 2/136 (1.5) 2/53 (3.8) 4/189 (2.1) 0.201
MACE, n (%) 57 (3.8) 44 (12.1) 101 (5.4) <0.001
MACCE, n (%) 65 (4.3) 47 (12.9) 112 (5.9) <0.001
Values are numbers and percentages. The p value is for categorical data from chi-
square test or Cox proportional hazard models. CVA - cerebrovascular accidents; 
MACE - major adverse cardiovascular events; MACCE - major adverse cardiovascular 
events or cerebrovascular events; MI - myocardial infarction; TLR - target lesion 
revascularization; TVR - target vessel revascularization. †Number of newly established 
CVA/number of previous cerebrovascular disease
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the multivariate analysis of all-cause mortality and MACCE at 
1-year. Age [hazard ratio (HR), 3.380; 95% confidence interval (CI), 
1.771–6.450; p<0.001] and previous cerebrovascular disease (HR, 
2.634; 95% CI, 1.702–4.077; p=<0.001) were independent predictors 
for 1-year MACCE. Also, cardiac death and previous cerebrovas-
cular disease showed significant correlation (HR, 2.338; 95% CI, 
1.024–4.962, p=0.018). Table 5 shows multivariate Cox regression 
analysis of MACCE in the elderly group at 1-year after PCI. Previ-
ous cerebrovascular disease was the only independent predictor 
(HR, 2.804, 95% CI, 1.290–6.093, p=0.009) in this age group.
Only one patient, a 66-year-old male who had undergone an 
ST elevation MI, experienced an acute stent thrombosis after 
PCI; therefore, we did not include stent thrombosis as an out-
come parameter in our study.
Discussion
The main findings from this prospective, multicenter, obser-
vational single-arm study showed that previous cerebrovascular 
disease is important independent predictor of MACCE in elderly 
Table 4. Multivariate analysis of all-cause mortality and MACCE at 1-year after index PCI
   All-cause mortality MACCE
  HR (95% CI) P HR (95% CI) P
Age, ≥75 y (n=365) 3.380 (1.771–6.450) <0.001 2.634 (1.702–4.077) <0.001
Men (n=1.327) 0.485 (0.244–0.965) 0.039 0.695 (0.451–1.070) 0.098
Previous cerebrovascular disease (n=189) 2.775 (1.312–5.870) 0.008 2.118 (1.119–4.008) 0.021
Estimated GFR (<60 mL/min/1.73 m2) (n=687) 2.303 (1.138–4.662) 0.020 1.405 (0.904–2.185) 0.131
Stable angina (n=824) 0.564 (0.310–1.027) 0.061 0.680 (0.454–1.020) 0.062
Unstable angina (n=505) 0.243 (0.092–0.643) 0.004 0.396 (0.226–0.694) 0.001
Left main CAD (n=61) 4.250 (1.579–11.44) 0.004 2.381 (1.012–5.603) 0.047
Right coronary artery lesion (n=824) 0.661 (0.318–1.374) 0.267 1.090 (0.741–1.603) 0.663
One-vessel disease (n=891) 0.700 (0.394–0.700) 0.473 0.925 (0.637–1.341) 0.680
Multi-vessel disease (n=993) 1.427 (0.804–2.536) 0.225 1.081 (0.746–1.569) 0.527
Number of diseased vessels 0.823 (0.392–1.727) 0.606 0.900 (0.545–1.484) 0.679
Number of treated vessels 2.052 (0.747–5.636) 0.163 1.434 (0.759–2.710) 0.266
Number of lesions 0.507 (0.152–1.693) 0.270 0.746 (0.391–1.424) 0.374
Number of treated lesions 1.589 (0.489–3.416) 0.429 1.487 (0.764–2.893) 0.243
CI - confidence interval; GFR - glomerular filtration rate; HR - hazard ratio; MACCE - major adverse cardiac or cerebrovascular events; PCI - percutaneous coronary intervention
Table 5. Multivariate Cox regression analysis of MACCE in the elderly at 1-year post-PCI
   <75 y (n=1.519) ≥75 y (n=365)
  HR (95% CI) P HR (95% CI) P
Previous cerebrovascular disease 1.326 (0.405–4.334) 0.641 2.804 (1.290–6.093) 0.009
Men 0.581 (0.300–1.125) 0.107 0.787 (0.437–1.418) 0.425
Estimated GFR <60 mL/min/1.73 m2 1.682 (0.975–2.900) 0.061 0.868 (0.436–1.730) 0.688
Stable angina 0.730 (0.430–1.237) 0.242 0.667 (0.349–1.278) 0.222
Unstable angina 0.315 (0.142–0.698) 0.004 0.576 (0.258–1.284) 0.178
Left main CAD 2.823 (0.979–8.142) 0.055 2.020 (0.455–8.969) 0.355
Right CAD 1.458 (0.876–2.426) 0.147 0.740 (0.401–1.366) 0.336
One-vessel disease 0.907 (0.557–1.477) 0.695 1.087 (0.611–1.931) 0.777
Multi-vessel disease 1.103 (0.677–1.795) 0.514 0.920 (0.518–1.636) 0.581
Number of diseased vessels 0.773 (0.372–1.606) 0.490 0.866 (0.407–1.842) 0.709
Number of treated vessels 1.566 (0.704–3.482) 0.271 1.675 (0.527–5.321) 0.382
Number of lesions 0.751 (0.344–1.639) 0.472 0.694 (0.209–2.305) 0.551
Number of treated lesions 1.758 (0.778–3.969) 0.175 0.856 (0.274–2.671) 0.789
CI - confidence interval; GFR - glomerular filtration rate; HR - hazard ratio; MACCE - major adverse cardiac or cerebrovascular events; PCI - percutaneous coronary intervention
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patients 1-year after PCI with Nobori® Biolimus A9-eluting stents 
especially in a series of South Korean population.
The 1-year cumulative rate of all-cause mortality was 2.6% 
(cardiac mortality was 1.3%) in this study. These rates were simi-
lar with the rates reported from the SORT OUT V trial (2.4%) and 
the LEADERS trial (3%) (12, 13).
The incidence of left main CAD increases with age (14). Thus, 
elderly patients are more likely to develop left main CAD than 
younger patients. Recent guidelines have considered PCI to 
be a compelling alternative to coronary artery bypass grafting 
(CABG) for left main coronary artery stenosis (15). At a median 
follow-up duration of 1,088 days, with respect to death, CVA, 
or MI, there were no differences between octogenarians who 
had been vascularized using PCI or CABG (16). Therefore, the 
long-term clinical outcomes following PCI in elderly patients ap-
pear to be acceptable. The present study also showed that left 
main CAD was not an independent predictor of MACCE in elderly 
patients one year after PCI (Table 4). According to our results, 
the authors carefully agree that PCI may provide greater benefit 
compared to CABG in elderly patients with left main CAD be-
cause they typically have more comorbidities and higher surgery 
risk than younger patients.
Patients who previously experienced cerebral infarctions 
are at high-risk of CAD (17), and CAD is a key cause of death in 
these patients (18). The findings from previous studies that have 
involved DES in CAD have shown reductions in the incidence 
of cardiac events associated with recurrent ischemia and lo- 
wer rates of angiographic restenosis compared with bare metal 
stents (19, 20). However, Sasao et al. (21) reported that the long-
term clinical outcomes were worse in patients with CAD who 
had experienced previous cerebral infarctions compared with 
those who had not experienced previous cerebral infarctions. 
Patients with cerebral infarction typically had motor dysfunction 
and could not perform a sufficient exercise stress test for as-
sessment of ischemic heart disease. Early detection of CAD oc-
curs less frequently in these patients. Therefore, early diagnosis 
and treatment of CAD in patients who have experienced previ-
ous cerebral infarctions is very important. 
Another study showed that patients who had experienced 
previous cerebral infarctions had a higher incidence of coronary 
risk factors and high-risk coronary anatomy, and poorer prog-
nosis after PCI than patients who had not experienced cerebral 
infarctions (22). Our study showed that previous cerebrovascular 
disease in elderly patients, who had undergone PCI, was a pre-
dictor of MACCE at 1-year (HR, 2.804; 95% CI, 1.290–6.093; p=0.009; 
Table 5). Previous cerebrovascular disease was one of the major 
determinants of all-cause mortality in our study (HR, 2.775; 95% 
CI, 1.312–5.870; p=0.008; Table 4). Previous cerebral infarction is 
known to be another risk factor for recurrent cerebral infarction. 
Uchiyama et al. (23) reported that patients with CAD who had co-
existing atherothrombotic disease were at high-risk of recurrence. 
The 1-year cumulative incidence of cerebrovascular disease in 
our study was 0.5% (eight patients) for the younger patient group 
and 0.8% (three patients) for the elderly patient group (p=0.506). 
Among the younger patients group, two had experienced hemor-
rhagic strokes (intraventricular hemorrhage and subdural hemo- 
rrhage) and six were ischemic stroke patients; whereas in the 
elderly patient group, one patient had experienced hemorrhagic 
stroke (cerebral hemorrhage) and two patients were ischemic 
stroke patients. The above three hemorrhagic stroke patients 
received operation. Six ischemic stroke patients of the younger 
patient group received thrombolytic therapy with intravenous (IV) 
or intra-arterial (IA) recombinant tissue plasminogen activator 
(rt-TPA, alteplase). Two ischemic stroke patients of the elderly 
patient group were treated with conventional anticoagulation 
therapy due to contraindication of thrombolytic therapy (≥75 
years). The incidence of recurrent CVA was higher in elderly pa-
tients than in younger patients but was not statically significant 
(3.8% vs. 1.5%, p=0.201; Table 3). Moreover, polyvascular disease 
is associated with increased event rates when compared with 
atherothrombotic disease in a single vascular bed (24). Pre-PCI 
cerebrovascular risk factor assessment as a part of an assess-
ment to determine preventive intervention or increased moni- 
toring may reduce the risk of future cerebrovascular events. 
Also, the proportion of patients with acute coronary syn-
drome in our study was 56.0% in the younger patient group and 
57.2% in the elderly patient group (Table 1), and subgroup analy-
sis for MACCE is shown in Figure 3. Our study included a large 
number of high-risk patients; therefore, we expect the current 
results to be meaningful. 
Although our study showed that previous cerebrovascular 
disease was an important independent predictor of MACCE in 
elderly patients 1 year after PCI, large, randomized, controlled 
clinical trials that include high-risk elderly patients will be re-
Figure 3. Subgroup analysis for MACCE
MACCE - major adverse cardiac or cerebrovascular events; LVEF - left ventricular ejection 
fraction; STEMI - ST-segment elevation myocardial infarction; NSTEMI - non-ST-segment 
elevation myocardial infarction; NYHA - New York Heart Association; IVUS - intravascular 
ultrasound
Hypertension    <0.001
 Yes 1.169 3.04 (1.95–4.75) <0.001
 No 715 3.09 (1.53–6.23) <0.001
Diabetes mellitus    <0.001
 Yes 713 3.41 (1.92–6.06) <0.001
 No 1.171 3.04 (1.85–5.01) <0.001
Dyslipidemia    0.049
 Yes 1.450 3.22 (2.04–5.11) <0.001
 No 434 2.59 (1.33–5.04) 0.005
LVEF    <0.001
 <50% 760 2.09 (0.95–4.58) 0.067
 ≥50% 1.124 0.87 (0.56–1.34) 0.526
STEMI    0.366
 Yes 330 2.60 (1.06–6.37) 0.037
 No 1.554 3.34 (2.21–5.07) <0.001
NSTEMI    0.010
 Yes 225 2.79 (1.25–6.21) 0.012
 No 1.659 3.10 (2.02–4.75) <0.001
NYHA class III ro IV    0.816
 Yes 146 1.656 (0.44–6.24) 0.456
 No 1.738 3.506(2.28–5.39) <0.001
IVUS    0.882
 Yes 369 8.272 (3.38–20.2) <0.001
 No 1.515 2.681 (1.75–4.10) <0.001
MACE
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quired to guide decision-making and improve PCI outcomes in 
this population. 
Study limitations
This study was limited because of its non-randomized design 
with short-term follow-up and the absence of another type of 
DES to facilitate direct comparisons. Furthermore, and like every 
“real-world” registry, there may have been some under-report-
ing and/or data might have been missing which is more likely to 
reflect physician selection bias toward patients with relatively 
good survival. Because the present study registry was conduct-
ed using only the Nobori® stent, the translation of our results in 
the present-day clinical practice may be inappropriate.
 Conclusion
Previous cerebrovascular disease is important independent 
predictor of MACCE in elderly patients during 1-year follow-up 
period after successful PCI with Nobori® Biolimus A9-eluting 
stents especially in a series of South Korean population. There-
fore, careful PCI with intensive monitoring and management can 
improve major clinical outcomes after successful PCI in elderly 
patients with previous cerebrovascular disease compared with 
younger patients.
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